Dr. Perl on Potential CAR T-Cell Therapies in Hematologic Malignancies

Video

Alexander E. Perl, MD, associate professor of medicine, University of Pennsylvania, discusses potential chimeric antigen receptor (CAR) T-cells in hematologic malignancies.

Alexander E. Perl, MD, associate professor of medicine, University of Pennsylvania, discusses potential chimeric antigen receptor (CAR) T-cell therapies in hematologic malignancies.

CAR T-cell therapy is being explored in acute myeloid leukemia (AML), but investigators have not determined which antigen is best to target, says Perl. There were data presented at the 2017 ASH Annual Meeting looking at CD123 and CD33-directed CARs, and other antigens that are on AML blasts. Perl says that it is hard to define an epitope to design a CAR against that is unique to the leukemia, and that is not shared with normal tissue or hematopoietic cells.

There is interest in other forms of B-cell lymphoma other than diffuse large B-cell lymphoma for which there is already a CAR T-cell therapy approval. Additionally, there is also interest in developing CAR T-cell therapies for multiple myeloma, says Perl.

Recent Videos
Michael Flanagan, PhD, chief scientific officer at Avidity
David Barrett, JD, the chief executive officer of ASGCT
David-Alexandre C. Gros, MD, Eledon’s chief executive officer
David Barrett, JD, the chief executive officer of ASGCT
Alfred L. Garfall, MD, MS, associate professor of medicine (hematology-oncology) and director, Autologous Hematopoietic Cell Transplantation, Cell Therapy and Transplant Program, Hospital of the University of Pennsylvania; and section chief, Multiple Myeloma, Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania,
Reena Sharma, MD, an adult metabolic consultant at Salford Royal Hospital
Nirav Shah, MD, MSHP, associate professor of medicine, at the Medical College of Wisconsin
Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center
Reena Sharma, MD, an adult metabolic consultant at Salford Royal Hospital
Mark Hamilton, MD, PhD, a hematology-oncology and bone marrow transplant (BMT) cell therapy fellow at Stanford University
© 2025 MJH Life Sciences

All rights reserved.